Hemispherx Biopharma Inc, Emerge Health deal

Hemispherx granted Emerge exclusive rights to develop and commercialize Ampligen rintatolimod in Australia and New Zealand to treat chronic fatigue syndrome. The double-stranded RNA antiviral agent that agonizes toll-like receptor 3 (TLR3) has completed a Phase III trial in chronic fatigue syndrome and myalgic encephalomyelitis. Emerge will seek Orphan Drug designation for Ampligen and plans to submit regulatory applications. Hemispherx will supply Ampligen to Emerge at an undisclosed transfer price. ...